Phase II Begins, Cashed Up with Healey In the Sights of Big Pharma $$$, page-213

First 213 Last

Share
Profile

Follow
Grainofsand

2,184 Posts.

1544

27/08/24

10:27

Post #: 75389938
Share

Originally posted by Hamondo: ↑

Why do you all go back to the gradual decline in the SP?

It wasn't a gradual decline, it was profit taking before the next announcement.

And if you need any more proof that MT has royally F'd this company, look at yesterdays announcement and the following SP movement. Fantastic news, fantastic results and the SP couldn't get over the CR figure.

Why? Because the people that can really move the SP are sitting back. They know that everyone is going to offload their 19c shares in the 20c range. So why bother buying in? The SP will not recover until the results are in a year from now.

Now lets say that the almighty MT had held the boards line and didn't resign for "personal reasons"....lol....

The SP would still be sitting at least 30c (no doubt), most likely higher after FDA, Heally and other announcements would that have pushed the price higher like it did with the previous results.

You do a cap raise at 30c or more and your now flush with twice the amount of cash, your SP is stable and the market is happy to buy in above the CR price because they can see the accounts with 30m or more and the results in the future. Even if there is profit taking above the CR price, they will still see benefit in buying.

I'm not saying that this company is not poised to become a major player and I'm more than happy to keep holding, I'm just saying the MT is the sole reason the SP is where it is at. plain and simple fact. It would never have declined to 16c without his leadership take over.

He should be sacked as CEO and a more suitable stable person with more leadership skill put in. Anyone that votes yes to his remuneration package that he will pout forward is a fool in my mind.

Expand

Taking a longer term view, I know where Michael is now taking us and I am very, very grateful we had the change of Board. Any sugar hit of sitting around 30c was bound to wear off under the old Board's direction. Much better to have gone through the pain when we did and rebuild from here. Those holding from here until 2026 will benefit far more than if the old regime remained.

PAA Price at posting: 18.5¢ Sentiment: Buy Disclosure: Held
22 Upvote

5 Great analysis

Reply

Top Stories

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

JDO

Timing will be everything for 'smashing' Hot Stock tip Judo Capital Holdings

RBA holds rates as ALP election campaigning kicks off – expect more political focus

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

HVN

Harvey Norman may appeal ASIC Federal Court case – the third lawsuit on its plate

There are more pages in this discussion • 251 more messages in this thread...

First 213 Last

Add NUZ (ASX) to my watchlist

(20min delay)
Last 19.0¢		Change 0.000(0.00%)		Mkt cap ! $93.42M

Open	High	Low	Value	Volume
19.5¢	19.5¢	19.0¢	$31.22K	164.2K

Buyers (Bids)

No.	Vol.	Price($)
7	362647	18.5¢

Sellers (Offers)

Price($)	Vol.	No.
19.0¢	66191	2

View Market Depth

No.	Vol.	Price($)
7	362647	0.185
5	327000	0.180
4	120797	0.175
3	68700	0.170
4	198200	0.160

Price($)	Vol.	No.
0.190	66191	2
0.195	285686	6
0.210	82780	3
0.215	206338	3
0.220	40000	1

Last trade - 14.37pm 05/11/2024 (20 minute delay)

NUZ (ASX) Chart

Phase II Begins, Cashed Up with Healey In the Sights of Big Pharma $$$, page-213

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Timing will be everything for 'smashing' Hot Stock tip Judo Capital Holdings

RBA holds rates as ALP election campaigning kicks off – expect more political focus

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Harvey Norman may appeal ASIC Federal Court case – the third lawsuit on its plate

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Phase II Begins, Cashed Up with Healey In the Sights of Big Pharma $$$, page-213

Top Stories

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Timing will be everything for 'smashing' Hot Stock tip Judo Capital Holdings

RBA holds rates as ALP election campaigning kicks off – expect more political focus

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Harvey Norman may appeal ASIC Federal Court case – the third lawsuit on its plate

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News